Acceleron Pharma

Investors & Media

Press Releases

Date Title and Summary
Toggle Summary Acceleron Announces Retirement of Director Jean George
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Apr. 7, 2020-- Acceleron Pharma Inc. (Nasdaq:XLRN), a biopharmaceutical company dedicated to the discovery, development, and commercialization of TGF-beta superfamily therapeutics to treat serious and rare diseases, today announced that Jean George is retiring
Toggle Summary U.S. Food and Drug Administration (FDA) Approves Reblozyl® (luspatercept-aamt), the First and Only Erythroid Maturation Agent, to Treat Anemia in Adults with Lower-Risk Myelodysplastic Syndromes (MDS)
The FDA approval marks the second indication for Reblozyl and the first new treatment option in over a decade for patients with MDS who require red blood cell (RBC) transfusions and have failed an erythropoiesis stimulating agent Reblozyl regulates late-stage RBC maturation to relieve patients from
Toggle Summary New England Journal of Medicine Publishes Results from Pivotal Phase 3 BELIEVE Trial of Reblozyl (luspatercept-aamt) in Adult Patients With Beta Thalassemia
Results demonstrate that treatment with Reblozyl provides significant reduction in transfusion burden for patients with beta thalassemia-associated anemia compared to placebo PRINCETON, N.J. & CAMBRIDGE, Mass. --(BUSINESS WIRE)--Mar. 26, 2020-- Bristol-Myers Squibb Company (NYSE:BMY) and Acceleron
Toggle Summary Acceleron Announces Topline Results from the Phase 2 Trial of ACE-083 in Patients with Charcot-Marie-Tooth Disease
– ACE-083 did not achieve statistically significant improvements in functional endpoints relative to placebo – – Acceleron to discontinue development of ACE-083 – CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Acceleron Pharma Inc. (NASDAQ:XLRN), a biopharmaceutical company dedicated to the discovery,
Toggle Summary Acceleron Reports Fourth Quarter and Full Year 2019 Operating and Financial Results
- REBLOZYL ® (luspatercept-aamt), a first-in-class erythroid maturation agent, was approved by the U.S. FDA for the treatment of anemia in adult patients with beta-thalassemia who require regular red blood cell transfusions; FDA review of the sBLA for the lower-risk myelodysplastic syndromes
Toggle Summary Acceleron to Participate in Two Upcoming Healthcare Investor Conferences
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb. 26, 2020-- Acceleron Pharma Inc. (Nasdaq:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta superfamily therapeutics intended to treat serious and rare diseases, today announced that senior management will participate in
Toggle Summary Acceleron to Webcast Fourth Quarter and Full Year 2019 Operating and Financial Results on February 27, 2020
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb. 18, 2020-- Acceleron Pharma Inc. (Nasdaq:XLRN) today announced it will host a webcast and conference call on Thursday, February 27, 2020 at 5:00 p.m. EST to discuss its fourth quarter and full year 2019 operating and financial results.
Toggle Summary Acceleron Announces Sotatercept Achieved Primary and Secondary Endpoints in the PULSAR Phase 2 Placebo-Controlled Trial in Patients with Pulmonary Arterial Hypertension
- The PULSAR trial achieved its primary endpoint: a statistically significant reduction in pulmonary vascular resistance - - The trial also achieved statistically significant improvements in the key secondary endpoint of six-minute walk distance (6MWD) and other secondary endpoints, including
Toggle Summary Acceleron Announces Change to Executive Management Team
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jan. 23, 2020-- Acceleron Pharma Inc. (Nasdaq:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta superfamily therapeutics to treat serious and rare diseases, announced today that John Quisel , J.D., Ph.D, Executive Vice
Toggle Summary New England Journal of Medicine Publishes Results of Pivotal Phase 3 Reblozyl® (luspatercept-aamt) MEDALIST Trial
Data from MEDALIST showed significant clinical benefit of Reblozyl in treating anemia in adults with myelodysplastic syndromes PRINCETON, N.J. & CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jan. 9, 2020-- Bristol-Myers Squibb Company (NYSE:BMY) and Acceleron Pharma Inc.